Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

被引：0
|
作者：
Phillip Chan
Orlanda Goh
Eugène Kroon
Donn Colby
Carlo Sacdalan
Suteeraporn Pinyakorn
Peeriya Prueksakaew
Peter Reiss
Jintanat Ananworanich
Victor Valcour
Serena Spudich
Robert Paul
机构：
[1] SEARCH,United States Military HIV Research Program
[2] The Thai Red Cross AIDS Research Centre,Department of Global Health, Amsterdam University Medical Centers
[3] The Henry M. Jackson Foundation for the Advancement of Military Medicine,Memory and Aging Center, Department of Neurology
[4] Walter Reed Army Institute of Research,Center for Neuroepidemiology and Clinical Neurological Research
[5] University of Amsterdam,Missouri Institute of Mental Health
[6] and Amsterdam Institute for Global Health and Development,undefined
[7] University of California San Francisco,undefined
[8] Yale University,undefined
[9] University of Missouri-St. Louis,undefined
来源：
AIDS Research and Therapy | / 17卷
关键词：
Dolutegravir; Neuropsychiatric adverse events; Depression; RV254; Cognitive performance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
    Twimukye, Adelline
    Laker, Miriam
    Odongpiny, Eva Agnes Laker
    Ajok, Florence
    Onen, Henry
    Kalule, Ivan
    Kajubi, Phoebe
    Seden, Kay
    Owarwo, Noela
    Kiragga, Agnes
    Armstrong-Hough, Mari
    Katahoire, Anne
    Mujugira, Andrew
    Lamorde, Mohammed
    Castelnuovo, Barbara
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [22] HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy
    Lahiri, Cecile D.
    Brown, Nakita L.
    Ryan, Kevin J.
    Acosta, Edward P.
    Sheth, Anandi N.
    Mehta, Cyra C.
    Ingersoll, Jessica
    Ofotokun, Ighovwerha
    AIDS, 2018, 32 (15) : 2151 - 2159
  • [23] Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy
    Gillman, J.
    Janulis, P.
    Gulick, R.
    Wallis, C.
    Berzins, B.
    Bedimo, R.
    Smith, K.
    Aboud, M.
    Taiwo, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [24] Treatment outcomes of low-level viremia among adults living with HIV on dolutegravir-based first line antiretroviral therapy in Botswana
    Bareng, Ontlametse T.
    Moyo, Sikhulile
    Mudanga, Mbatshi
    Sebina, Kagiso
    Koofhethile, Catherine
    Choga, Wonderful
    Gobe, Irene
    Motswaledi, Modisa
    Maruapula, Docas
    Moraka, Natasha
    Musonda, Rosemary
    Nkomo, Joseph
    Ramaabya, Dinah
    Chebani, Tony
    Makuruetsa, Penny
    Makhema, Joseph
    Gaseitsiwe, Simani
    BMJ GLOBAL HEALTH, 2023, 8 (SUPPL_10): : A24 - A24
  • [25] Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication
    Parienti, Jean-Jacques
    Fournier, Anna L.
    Cotte, Laurent
    Schneider, Marie-Paule
    Etienne, Manuel
    Unal, Guillemette
    Perre, Philippe
    Dutheil, Jean-Jacques
    Morilland-Lecoq, Elodie
    Chaillot, Fabien
    Bangsberg, David R.
    Gagneux-Brunon, Amandine
    Prazuck, Thierry
    Cavassini, Matthias
    Verdon, Renaud
    Hocqueloux, Laurent
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
  • [26] Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients
    Bruzzese, Eugenia
    Lo Vecchio, Andrea
    Smarrazzo, Andrea
    Tambaro, Orsola
    Palmiero, Giulia
    Bonadies, Giovanni
    Guarino, Alfredo
    ITALIAN JOURNAL OF PEDIATRICS, 2018, 44
  • [27] Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
    Fimbo, Adam
    Mwalwisi, Yonah H.
    Mwamwitwa, Kissa
    Matiko, Damas
    Mfinanga, Elirehema
    Lyimo, Johnson
    Sabasaba, Amon
    Missago, Seth
    Bukundi, Elias
    Gotora, Goodluck
    Respick, Dorice
    Nkayamba, Alex
    Masunga, Emmanuel
    Mnkugwe, Rajabu Hussein
    Kunambi, Peter P.
    Munishi, Castory
    Musanhu, Christine Chiedza
    Minzi, Omary M. S.
    Mlugu, Eulambius M.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [28] Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy
    Gillman, Jason
    Janulis, Patrick
    Gulick, Roy
    Wallis, Carole L.
    Berzins, Baiba
    Bedimo, Roger
    Smith, Kimberly
    Aboud, Michael
    Taiwo, Babafemi
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (08) : 2365 - 2369
  • [29] Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
    Adam Fimbo
    Yonah H. Mwalwisi
    Kissa Mwamwitwa
    Damas Matiko
    Elirehema Mfinanga
    Johnson Lyimo
    Amon Sabasaba
    Seth Missago
    Elias Bukundi
    Goodluck Gotora
    Dorice Respick
    Alex Nkayamba
    Emmanuel Masunga
    Rajabu Hussein Mnkugwe
    Peter P. Kunambi
    Castory Munishi
    Christine Chiedza Musanhu
    Omary M. S. Minzi
    Eulambius M. Mlugu
    Scientific Reports, 14
  • [30] Using Climate-HIV to describe real-world clinical outcomes for people living with HIV on dolutegravir-based regimens
    Okoli, C.
    Schwenk, A.
    Radford, M.
    Myland, M.
    Taylor, S.
    van Wyk, J.
    Barnes, J.
    Fox, A.
    Reeves, I.
    Munshi, S.
    Croucher, A.
    Grimson, F.
    Paice, A.
    Boxall, N.
    Darley, A. A.
    Benn, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345